Compare CLIR & LITS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLIR | LITS |
|---|---|---|
| Founded | 2008 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.6M | 25.7M |
| IPO Year | 2011 | 2003 |
| Metric | CLIR | LITS |
|---|---|---|
| Price | $3.79 | $1.27 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $20.00 | N/A |
| AVG Volume (30 Days) | 20.7K | ★ 408.4K |
| Earning Date | 04-09-2026 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $530,000.00 | N/A |
| Revenue This Year | $34.29 | N/A |
| Revenue Next Year | $67.31 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.39 | $0.69 |
| 52 Week High | $7.56 | $2.97 |
| Indicator | CLIR | LITS |
|---|---|---|
| Relative Strength Index (RSI) | 44.74 | 68.16 |
| Support Level | $3.75 | $1.10 |
| Resistance Level | $4.30 | $1.65 |
| Average True Range (ATR) | 0.33 | 0.10 |
| MACD | -0.06 | 0.01 |
| Stochastic Oscillator | 26.23 | 81.15 |
ClearSign Technologies Corp is engaged in designing and develop technologies for the purpose of decarbonization and improving key performance characteristics of industrial and commercial combustion systems, including emission and operational performance, energy efficiency and overall cost-effectiveness. Its ClearSign Core technology has been proved to be in full scale industrial test furnaces and boilers and first customer installations are currently operating in normal commercial applications The company offers products that include process burners, boiler burners, flares, and ClearSign Eye. The company operates in one segment: Combustion segment. The products of the company include: Process Burners, Midstream and Power, Flares, Boiler Burners, and Sensing Technology.
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.